Literatur
- 1
Hyde G M, Jewell D P.
Review article: the management of severe ulcerative colitis.
Aliment Pharmacol Ther.
1997;
11
419-424 (III)
- 2
Travis S P, Farrant J M, Ricketts C. et al .
Predicting outcome in severe ulcerative colitis.
Gut.
1996;
38
905-910 (III)
- 3
Wijers O B, Tio T L, Tytgat G N.
Ultrasonography and endosonography in the diagnosis and management of inflammatory
bowel disease.
Endoscopy.
1992;
24
559-564 (III)
- 4
Schwerk W BBK, Raith M.
A prospective evaluation of high resolution sonography in the diagnosis of inflammatory
bowel disease.
Eur J Gastroenterol Hepatol.
1992;
172-182 (III)
- 5
Gionchetti P, Rizzello F, Venturi A. et al .
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis.
Dis Colon Rectum.
1998;
41
93-97 (Ib)
- 6
Campieri M, Gionchetti P, Belluzzi A. et al .
5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?.
J Clin Gastroenterol.
1988;
10
406-409 (Ib)
- 7
Danish 5-ASA Group .
Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis.
A randomized, double-blind multicenter trial.
Dig Dis Sci.
1987;
32
598-602 (Ib)
- 8
Campieri M, Gionchetti P, Belluzzi A. et al .
Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative
colitis.
Dig Dis Sci.
1987;
32
67S-70S (Ib)
- 9
Marshall J K, Irvine E J.
Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis.
Aliment Pharmacol Ther.
1995;
9
293-300 (Ia)
- 10
Safdi M, DeMicco M, Sninsky C. et al .
A double-blind comparison of oral versus rectal mesalamine versus combination therapy
in the treatment of distal ulcerative colitis.
Am J Gastroenterol.
1997;
92
1867-1871 (Ib)
- 11
Hanauer S B.
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative
proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA
Enema Study Group.
Inflamm Bowel Dis.
1998;
4
79-83 (Ib)
- 12
Campieri M, Gionchetti P, Belluzzi A. et al .
Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative
colitis.
Gut.
1991;
32
929-931 (Ib)
- 13
Sinha A, Nightingale J, West K P. et al .
Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided
ulcerative colitis or proctitis.
N Engl J Med.
2003;
349
350-357 (Ib)
- 14
Marshall J K, Irvine E J.
Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.
Gut.
1997;
40
775-781 (Ia)
- 15
Danielsson A, Hellers G, Lyrenas E. et al .
A controlled randomized trial of budesonide versus prednisolone retention enemas in
active distal ulcerative colitis.
Scand J Gastroenterol.
1987;
22
987-992 (Ib)
- 16
Danielsson A, Lofberg R, Persson T. et al .
A steroid enema, budesonide, lacking systemic effects for the treatment of distal
ulcerative colitis or proctitis.
Scand J Gastroenterol.
1992;
27
9-12 (Ib)
- 17
Lofberg R, Ostergaard T homsen O, Langholz E. et al .
Budesonide versus prednisolone retention enemas in active distal ulcerative colitis.
Aliment Pharmacol Ther.
1994;
8
623-629 (Ib)
- 18
Mulder C J, Fockens P, Meijer J W. et al .
Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination
of both (3 mg/2 g) as retention enemas in active ulcerative proctitis.
Eur J Gastroenterol Hepatol.
1996;
8
549-553 (Ib)
- 19
Lofberg R, Danielsson A, Suhr O. et al .
Oral budesonide versus prednisolone in patients with active extensive and left-sided
ulcerative colitis.
Gastroenterology.
1996;
110
1713-1718 (Ib)
- 20
Truelove S C, Witts L J.
Cortisone in ulcerative colitis; final report on a therapeutic trial.
Br Med J.
1955;
1041-1048 (III)
- 21
Vernia P, Marcheggiano A, Caprilli R. et al .
Short-chain fatty acid topical treatment in distal ulcerative colitis.
Aliment Pharmacol Ther.
1995;
9
309-313 (Ib)
- 22
Steinhart A H, Hiruki T, Brzezinski A. et al .
Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial.
Aliment Pharmacol Ther.
1996;
10
729-736 (IIa)
- 23
Vernia P, Annese V, Bresci G. et al .
Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis:
results of a multicentre trial.
Eur J Clin Invest.
2003;
33
244-248 (Ib)
- 24
Baron J H, Connell A M, Kanaghinis T G. et al .
Out-patient treatment of ulcerative colitis. Comparison between three doses of oral
prednisone.
Br Med J.
1962;
5302
441-443 (IIb)
- 25
Margolin M L, Krumholz M P, Fochios S E. et al .
Clinical trials in ulcerative colitis: II. Historical review.
Am J Gastroenterol.
1988;
83
227-243 (IV)
- 26
Landi B, Anh T N, Cortot A. et al .
Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical
trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives.
Gastroenterology.
1992;
102
1647-1653 (Ib)
- 27
Schroeder K W, Tremaine W J, Ilstrup D M.
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative
colitis. A randomized study.
N Engl J Med.
1987;
317
1625-1629 (Ib)
- 28
Hanauer S, Schwartz J, Robinson M. et al .
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled
trial. Pentasa Study Group.
Am J Gastroenterol.
1993;
88
1188-1197 (Ib)
- 29
Hanauer S B.
Balsalazide led to greater remission rates and tolerance than mesalamine in acute
ulcerative colitis.
Gut.
1999;
44
455 (Ib)
- 30
Sninsky C A, Cort D H, Shanahan F. et al .
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter
study.
Ann Intern Med.
1991;
115
350-355 (Ib)
- 31
Meyers S, Sachar D B, Present D H. et al .
Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant
of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging
clinical trial.
Gastroenterology.
1987;
93
1255-1262 (Ib)
- 32
Feurle G E, Theuer D, Velasco S. et al .
Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis:
a randomised double blind trial.
Gut.
1989;
30
1354-1361 (Ib)
- 33
Rachmilewitz D.
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of
active ulcerative colitis: a randomised trial.
Bmj.
1989;
298
82-86 (III)
- 34
Kruis W, Brandes J W, Schreiber S. et al .
Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
Aliment Pharmacol Ther.
1998;
12
707-715 (Ib)
- 35
Green J R, Lobo A J, Holdsworth C D. et al .
Balsalazide is more effective and better tolerated than mesalamine in the treatment
of acute ulcerative colitis. The Abacus Investigator Group.
Gastroenterology.
1998;
114
15-22 (Ib)
- 36
Levine D SPR, Riff D, Koval G. et al .
A multicenter double-blind dose-response trial of colazide and asacol for mild-moderately
active ulcerative colitis.
Gastroenterology.
1997;
112
A1026 (Ib)
- 37
Sutherland L R, May G R, Shaffer E A.
Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment
of ulcerative colitis.
Ann Intern Med.
1993;
118
540-549 (Ia)
- 38
Oshitani N, Kitano A, Matsumoto T. et al .
Corticosteroids for the management of ulcerative colitis.
J Gastroenterol.
1995;
30 (Suppl 8)
118-120 (IIb)
- 39
D’Haens G, Lemmens L, Geboes K. et al .
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for
severe attacks of ulcerative colitis.
Gastroenterology.
2001;
120
1323-1329 (Ib)
- 40
Meyers S, Lerer P K, Feuer E J. et al .
Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results
of a prospective, randomized, double-blind clinical trial.
J Clin Gastroenterol.
1987;
9
50-54 (III)
- 41
Folwaczny C, Wiebecke B, Loeschke K.
Unfractioned heparin in the therapy of patients with highly active inflammatory bowel
disease.
Am J Gastroenterol.
1999;
94
1551-1555 (III)
- 42
Ang Y S, Mahmud N, White B. et al .
Randomized comparison of unfractionated heparin with corticosteroids in severe active
inflammatory bowel disease.
Aliment Pharmacol Ther.
2000;
14
1015-1022 (Ib)
- 43
Evans R C, Wong V S, Morris A I. et al .
Treatment of corticosteroid-resistant ulcerative colitis with heparin-a report of
16 cases.
Aliment Pharmacol Ther.
1997;
11
1037-1040 (III)
- 44
Evans R C, Clarke L, Heath P. et al .
Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.
Aliment Pharmacol Ther.
1997;
11
1031-1035 (III)
- 45
Probert C S, Hearing S D, Schreiber S. et al .
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised
controlled trial.
Gut.
2003;
52
998-1002 (Ib)
- 46
Sawada K, Muto T, Shimoyama T. et al .
Multicenter randomized controlled trial for the treatment of ulcerative colitis with
a leukocytapheresis column.
Curr Pharm Des.
2003;
9
307-321 (Ib)
Prof. Dr. W. Fleig
Martin-Luther-Universität Halle-Wittenberg, Klinik u. Poliklinik für Innere Medizin
I
Ernst-Grube-Str. 40
06120 Halle
Telefon: ++ 49/3 45/5 57 26 61
Fax: ++ 49/3 45/5 57 22 53
eMail: wolfgang.fleig@medizin.uni-halle.de
